Martin Edwards, BSc (Hons), MB.ChB (Hons), MRCP, MRCGP (Dist), FFPM, MBA
Martin is Senior Partner at Novo Ventures, the venture capital arm of Novo A/S. He is Chairman of Vantia Ltd and KalVista Pharmaceuticals Ltd, and a Director on the boards of F2G Ltd, CoLucid Pharmaceuticals, Inc., Nuvelution Pharma Inc., Tarsa Therapeutics Inc. , Acacia Pharma Ltd and Karus Therapeutics Ltd..
Prior to this, Martin was CEO of ReNeuron Ltd from 1998 to 2003 taking the company public in 2001. He was world-wide head of drug development for Novo Nordisk from 1994 to 1998, Senior Vice President at Novo Nordisk (USA) from 1992 to 1994 and CMO/Vice President at Zymogenetics from 1989 to 1992.
Martin trained in physiology and medicine in Manchester UK and in business at Warwick University. In 2009 Martin was made Adjunct Professor at CBS Executive in Copenhagen where he continues to teach and examine.